- Home
- EBMT vs KZIA Comparison
EBMT vs KZIA Comparison
Compare EBMT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | KZIA |
|---|---|---|
| Founded | 1922 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.7M | 186.7M |
| IPO Year | 2009 | 2002 |
Fundamental Metrics
Financial Performance| Metric | EBMT | KZIA |
|---|---|---|
| Price | $20.73 | $8.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $24.00 | ★ $28.36 |
| AVG Volume (30 Days) | 19.8K | ★ 277.8K |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ 53.23 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $3.84 | N/A |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.80 | $4.86 |
| 52 Week High | $24.66 | $17.40 |
Technical Indicators
Market Signals| Indicator | EBMT | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 32.99 |
| Support Level | $20.00 | $5.15 |
| Resistance Level | $22.63 | $14.85 |
| Average True Range (ATR) | 0.56 | 0.64 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 17.02 | 7.47 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.